Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.

Recorded On: 06/13/2019

HCV: DAA therapy for kidney/liver transplant recipients

Complete

Failed

Available

Locked

Article

Select the "View On-Demand Recording" button to begin.

Select the "View On-Demand Recording" button to begin. HCV: DAA therapy for kidney/liver transplant recipients

You must register to access.